Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Nofar Bahar"'
Autor:
Boris M. Baranovski, Omer Nisim, Ronen Schuster, Nofar Bahar, Eli C. Lewis, Galit Shahaf, Noa Kalay, Pablo Cal, Eran Schenker, Eyal Ozeri, David E. Ochayon, Mark Mizrahi, Pnina Strauss
Publikováno v:
The Journal of Pharmacology and Experimental Therapeutics
Lifelong weekly infusions of human α1-antitrypsin (hAAT) are currently administered as augmentation therapy for patients with genetic AAT deficiency (AATD). Several recent clinical trials attempt to extend hAAT therapy to conditions outside AATD, in
Autor:
Boris M. Baranovski, Nofar Bahar, Ido Brami, Ronen Schuster, Noa Kalay, David E. Ochayon, Mark Mizrahi, Gabriella S. Freixo-Lima, Ofer Guttman, Ziv Kaner, Eli C. Lewis
Summary One would assume that the anti-inflammatory activity of α1-anti-trypsin (AAT) is the result of inhibiting neutrophil enzymes. However, AAT exhibits tolerogenic activities that are difficult to explain by serine-protease inhibition or by redu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c704d4f3287b82b376773f5cce44aea3
https://europepmc.org/articles/PMC4298394/
https://europepmc.org/articles/PMC4298394/
Autor:
Boris M. Baranovski, Eli C. Lewis, Mark Mizrahi, Nofar Bahar, David E. Ochayon, Galit Shahaf, Ziv Kaner
Publikováno v:
The Journal of infectious diseases. 211(9)
Background Severe bacterial infection can cause sepsis, multiple organ dysfunction syndrome (MODS), and death. Human α1-antitrypsin (hAAT) is an antiinflammatory, immune-modulating, and tissue-protective circulating serine-protease inhibitor, with l